BioStock: Status Report Cereno Scientific – an undervalued Phase II company

27 November, 2018

BioStock has performed a Status Report of Cereno Scientific, a company that develops CS1 – a thrombosis-preventing drug based on the body´s own intelligent clot-busting system. The Phase II candidate has the potential to redefine the field of thrombosis prevention.

To read the Status Report, click here